{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T08:03:41Z","timestamp":1785830621440,"version":"3.56.0"},"reference-count":61,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2021,12,1]]},"DOI":"10.1001\/jamaoncol.2021.4083","type":"journal-article","created":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T16:07:34Z","timestamp":1630598854000},"page":"1882","source":"Crossref","is-referenced-by-count":53,"title":["COVID-19 and Cancer"],"prefix":"10.1001","volume":"7","author":[{"given":"Aakash","family":"Desai","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, Mayo Clinic, Rochester, Minnesota"},{"name":"Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turab J.","family":"Mohammed","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Connecticut, Farmington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narjust","family":"Duma","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Medical Oncology and Palliative Care, University of Wisconsin, Madison"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina C.","family":"Garassino","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa K.","family":"Hicks","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, St. Michael\u2019s Hospital, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M.","family":"Kuderer","sequence":"additional","affiliation":[{"name":"Advanced Cancer Research Group, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary H.","family":"Lyman","sequence":"additional","affiliation":[{"name":"Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington"},{"name":"Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington"},{"name":"Division of Oncology, Department of Medicine, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Mishra","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Pinato","sequence":"additional","affiliation":[{"name":"Department of Surgery and Cancer, Imperial College London, London, United Kingdom"},{"name":"Division of Oncology, Department of Translational Medicine, Piemonte Orientale University, Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian I.","family":"Rini","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solange","family":"Peters","sequence":"additional","affiliation":[{"name":"Oncology Department, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy L.","family":"Warner","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer G.","family":"Whisenant","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Wood","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, University of North Carolina at Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Thompson","sequence":"additional","affiliation":[{"name":"Aurora Cancer Care, Advocate Aurora Health, Milwaukee, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9","key":"crv210008r1","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1002\/cncr.v127.9","article-title":"Mortality in hospitalized patients with cancer and coronavirus disease 2019: a systematic review and meta-analysis of cohort studies.","volume":"127","author":"Desai","year":"2021","journal-title":"Cancer"},{"issue":"30","key":"crv210008r2","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1200\/JCO.20.01307","article-title":"Chemotherapy and COVID-19 outcomes in patients with cancer.","volume":"38","author":"Jee","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7","key":"crv210008r3","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S1470-2045(20)30310-7","article-title":"Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study.","volume":"21","author":"Yang","year":"2020","journal-title":"Lancet Oncol"},{"issue":"5","key":"crv210008r4","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.ccell.2020.09.018","article-title":"COVID-19 and cancer: current challenges and perspectives.","volume":"38","author":"Bakouny","year":"2020","journal-title":"Cancer Cell"},{"issue":"2","key":"crv210008r5","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1001\/jamaoncol.2020.6178","article-title":"Analyses of risk, racial disparity, and outcomes among US patients with cancer and COVID-19 infection.","volume":"7","author":"Wang","year":"2021","journal-title":"JAMA Oncol"},{"issue":"2","key":"crv210008r6","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1001\/jamaoncol.2020.5461","article-title":"Use of real-world electronic health records to estimate risk, risk factors, and disparities for COVID-19 in patients with cancer.","volume":"7","author":"Desai","year":"2021","journal-title":"JAMA Oncol"},{"key":"crv210008r7","article-title":"Dexamethasone in hospitalized patients with Covid-19.","author":"The RECOVERY Collaborative Group","journal-title":"N Engl J Med"},{"issue":"13","key":"crv210008r8","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jama.2020.17022","article-title":"Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial.","volume":"324","author":"Angus","year":"2020","journal-title":"JAMA"},{"issue":"13","key":"crv210008r9","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1001\/jama.2020.16761","article-title":"Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial.","volume":"324","author":"Dequin","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"crv210008r10","doi-asserted-by":"publisher","first-page":"354","DOI":"10.5935\/0103-507X.20200063","article-title":"COVID-19\u2013associated ARDS treated with dexamethasone (CoDEX): study design and rationale for a randomized trial.","volume":"32","author":"Tomazini","year":"2020","journal-title":"Rev Bras Ter Intensiva"},{"issue":"12","key":"crv210008r11","doi-asserted-by":"publisher","first-page":"6417","DOI":"10.1172\/JCI140617","article-title":"Corticosteroid treatment in severe COVID-19 patients with acute respiratory distress syndrome.","volume":"130","author":"Liu","year":"2020","journal-title":"J Clin Invest"},{"issue":"9","key":"crv210008r12","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1136\/annrheumdis-2020-218479","article-title":"Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study.","volume":"79","author":"Ramiro","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"crv210008r14","author":"Kuderer"},{"issue":"10","key":"crv210008r15","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1080\/07357907.2020.1841922","article-title":"Randomized controlled trials versus real-world data in the COVID-19 era: a false narrative.","volume":"38","author":"Lyman","year":"2020","journal-title":"Cancer Invest"},{"issue":"5","key":"crv210008r16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s43018-020-0065-z","article-title":"Crowdsourcing a crisis response for COVID-19 in oncology.","volume":"1","author":"Desai","year":"2020","journal-title":"Nat Cancer"},{"issue":"10241","key":"crv210008r19","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/S0140-6736(20)31187-9","article-title":"Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.","volume":"395","author":"Kuderer","year":"2020","journal-title":"Lancet"},{"key":"crv210008r20","author":"Warner"},{"issue":"10257","key":"crv210008r21","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/S0140-6736(20)32065-1","article-title":"Cancer and COVID-19\u2014authors\u2019 reply.","volume":"396","author":"Kuderer","year":"2020","journal-title":"Lancet"},{"issue":"10","key":"crv210008r22","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1158\/2159-8290.CD-20-0941","article-title":"Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: a COVID-19 and Cancer Consortium (CCC19) cohort study.","volume":"10","author":"Rivera","year":"2020","journal-title":"Cancer Discov"},{"key":"crv210008r23"},{"key":"crv210008r25"},{"key":"crv210008r26"},{"key":"crv210008r27","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2021.1799","article-title":"Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19.","author":"Thompson","year":"2021","journal-title":"JAMA Oncol"},{"issue":"7","key":"crv210008r29","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.3390\/cancers12071841","article-title":"Presenting features and early mortality from SARS-CoV-2 infection in cancer patients during the initial stage of the COVID-19 pandemic in Europe.","volume":"12","author":"Pinato","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"10","key":"crv210008r30","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1158\/2159-8290.CD-20-0773","article-title":"Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients.","volume":"10","author":"Pinato","year":"2020","journal-title":"Cancer Discov"},{"key":"crv210008r32","doi-asserted-by":"publisher","first-page":"S992","DOI":"10.1016\/j.annonc.2020.08.1735","article-title":"Prospective data of first 1,797 hospitalised patients with cancer and COVID-19 derived from the COVID-19 Clinical Information Network and International Severe Acute Respiratory and Emerging Infections Consortium, WHO Coronavirus Clinical Characterisation Consortium.","volume":"31","author":"Palmieri","year":"2020","journal-title":"Ann Oncol"},{"key":"crv210008r33","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejca.2021.03.035","article-title":"Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study.","volume":"150","author":"Pinato","year":"2021","journal-title":"Eur J Cancer"},{"issue":"3","key":"crv210008r34","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002277","article-title":"Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid inflammatory score.","volume":"9","author":"Dettorre","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"10241","key":"crv210008r35","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/S0140-6736(20)31173-9","article-title":"COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study.","volume":"395","author":"Lee","year":"2020","journal-title":"Lancet"},{"issue":"7","key":"crv210008r36","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S1470-2045(20)30314-4","article-title":"COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study.","volume":"21","author":"Garassino","year":"2020","journal-title":"Lancet Oncol"},{"key":"crv210008r37"},{"key":"crv210008r38","doi-asserted-by":"publisher","first-page":"S1204","DOI":"10.1016\/j.annonc.2020.08.2316","article-title":"Defining COVID-19 outcomes in thoracic cancer patients: TERAVOLT (Thoracic Cancers International COVID 19 Collaboration).","volume":"31","author":"Baena Espinar","year":"2020","journal-title":"Ann Oncol"},{"key":"crv210008r41"},{"issue":"23","key":"crv210008r44","doi-asserted-by":"publisher","first-page":"5966","DOI":"10.1182\/bloodadvances.2020003170","article-title":"Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub.","volume":"4","author":"Wood","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"crv210008r46","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ccell.2020.10.013","article-title":"The HOLA COVID-19 study: an international effort to determine how COVID-19 has impacted oncology practices in Latin America.","volume":"38","author":"Bernabe-Ramirez","year":"2020","journal-title":"Cancer Cell"},{"key":"crv210008r50","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ejca.2020.09.027","article-title":"Dutch Oncology COVID-19 Consortium: outcome of COVID-19 in patients with cancer in a nationwide cohort study.","volume":"141","author":"de Joode","year":"2020","journal-title":"Eur J Cancer"},{"issue":"26","key":"crv210008r55","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1182\/blood.2020008150","article-title":"Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set.","volume":"136","author":"Chari","year":"2020","journal-title":"Blood"},{"issue":"3","key":"crv210008r56","doi-asserted-by":"publisher","first-page":"e185","DOI":"10.1016\/S2352-3026(20)30429-4","article-title":"Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study.","volume":"8","author":"Sharma","year":"2021","journal-title":"Lancet Haematol"},{"issue":"1","key":"crv210008r57","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1182\/blood.2020006216","article-title":"Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?","volume":"136","author":"Frigault","year":"2020","journal-title":"Blood"},{"issue":"4","key":"crv210008r60","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.semradonc.2019.05.010","article-title":"The evolving use of electronic health records (EHR) for research.","volume":"29","author":"Kim","year":"2019","journal-title":"Semin Radiat Oncol"},{"issue":"2","key":"crv210008r61","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1001\/jamaoncol.2020.6639","article-title":"Scientific rigor in the age of COVID-19.","volume":"7","author":"Shyr","year":"2021","journal-title":"JAMA Oncol"},{"key":"crv210008r24","author":"Li","year":"2020"},{"key":"crv210008r13","unstructured":"American Cancer Society. COVID-19 vaccines in people with cancer. American Cancer Society. Updated July 13, 2021. Accessed February 4, 2021. https:\/\/www.cancer.org\/treatment\/treatments-and-side-effects\/physical-side-effects\/low-blood-counts\/infections\/covid-19-vaccines-in-people-with-cancer.html"},{"key":"crv210008r17","unstructured":"@ADesaiMD. COVID19nCancer is important! Data out of China indicates higher risk. Lets collaborate to survey data, provide update on the effective risk mitigation strategies @NIH designated cancer centers for #oncologists #cancer patients @GlopesMd @marklewismd @ASCO @ASH_hematology #SoMe. https:\/\/twitter.com\/ADesaiMD\/status\/1238605058775732224. Posted March 13, 2020. Accessed February 7, 2021."},{"key":"crv210008r18","unstructured":"COVID-19 and Cancer Consortium. What information is collected in the CCC19 survey? COVID-19 and Cancer Consortium; 2020. Accessed June 2021. https:\/\/ccc19.org\/faqs"},{"key":"crv210008r28","unstructured":"COVID-19 and Cancer Consortium. Publications. COVID-19 and Cancer Consortium; 2021 Accessed August 3, 2021. https:\/\/ccc19.org\/publications"},{"key":"crv210008r31","unstructured":"NIHR Imperial Biomedical Research Centre. OnCovid: natural history and outcomes of cancer patients during the COVID19 epidemic. National Institute for Health Research; 2021. Accessed August 3, 2021. https:\/\/imperialbrc.nihr.ac.uk\/research\/covid-19\/covid-19-ongoing-studies\/oncovid"},{"key":"crv210008r39","unstructured":"American Society of Clinical Oncology. ASCO COVID-19 Registry data dashboard. American Society of Clinical Oncology; 2021. Accessed June 2, 2021. https:\/\/www.asco.org\/asco-coronavirus-information\/coronavirus-registry\/covid-19-registry-data-dashboard"},{"key":"crv210008r40","unstructured":"American Society of Clinical Oncology. ASCO COVID-19 Registry data dashboard. American Society of Clinical Oncology. November 3, 2020. Accessed December 5, 2020. https:\/\/www.asco.org\/asco-coronavirus-information\/coronavirus-registry\/covid-19-registry-data-dashboard"},{"key":"crv210008r42","unstructured":"ASH Research Collaborative. COVID-19 Registry data summaries. ASH Research Collaborative. Updated July 18, 2021. Accessed June 2, 2021. https:\/\/www.ashresearchcollaborative.org\/s\/covid-19-registry\/data-summaries"},{"key":"crv210008r43","unstructured":"ASH Research Collaborative. COVID 19 Registry data summaries. ASH Research Collaborative. Updated July 18, 2021. Accessed December 10, 2020. https:\/\/www.ashresearchcollaborative.org\/s\/covid-19-registry-data-summaries"},{"key":"crv210008r45","unstructured":"Wood W, Neuberg DS, Thompson JC, et al. Outcomes of patients with hematologic malignancies and COVID-19 infection: a report from the ASH Research Collaborative Data Hub. Abstract presented at: virtual annual meeting and exposition of the American Society of Hematology; December 5, 2020. Accessed January 31, 2021. https:\/\/ash.confex.com\/ash\/2020\/webprogram\/Paper141327.html"},{"key":"crv210008r47","unstructured":"Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Australia (CORIA): a multisite registry and optional biorepository in people with COVID-19 and selected conditions affecting immune function. ClinicalTrials.gov identifier: NCT04354818. Updated July 28, 2020. Accessed December 5, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04354818"},{"key":"crv210008r48","unstructured":"ESMO. ESMO-CoCARE registry. European Society for Medical Oncology; 2020. Accessed December 5, 2020. https:\/\/www.esmo.org\/covid-19-and-cancer\/collaborating-on-registries-studies-and-surveys\/esmo-cocare-registry"},{"key":"crv210008r49","unstructured":"European Society for Medical Oncology. ESMO Congress 2021. European Society for Medical Oncology; 2020. Accessed August 3, 2021. https:\/\/www.esmo.org\/meetings\/esmo-congress-2021"},{"key":"crv210008r51","unstructured":"National Cancer Institute. NCI COVID-19 in Cancer Patients Study (NCCAPS). National Cancer Institute. Updated November 9, 2020. Accessed December 5, 2020. https:\/\/www.cancer.gov\/research\/key-initiatives\/covid-19\/coronavirus-research-initiatives\/nccaps"},{"key":"crv210008r52","unstructured":"Ahlstrom J. Myeloma Crowd introduces largest COVID-19 multiple myeloma patient study. Myeloma Crowd by HealthTree, Crowd Care Foundation. April 16, 2020. Accessed August 3, 2021. https:\/\/www.myelomacrowd.org\/the-myeloma-crowd-introduces-the-largest-covid-19-multiple-myeloma-study\/"},{"key":"crv210008r53","unstructured":"Myeloma Crowd by HealthTree. Improving myeloma patient outcomes and accelerating a cure. Myeloma Crowd by HealthTree, Crowd Care Foundation; 2021. Accessed August 3, 2021. https:\/\/www.myelomacrowd.org\/healthtree\/"},{"key":"crv210008r54","unstructured":"Multiple Myeloma Research Foundation. MMRF partners with Dana Farber Cancer Institute on COVID-19 IMPACT research study (antibody-based COVID-19 testing). Multiple Myeloma Research Foundation. July 28, 2021. Accessed August 3, 2021. https:\/\/themmrf.org\/2021\/07\/28\/mmrf-partners-with-dana-farber-cancer-institute-on-covid-19-impact-research-study-antibody-based-covid-19-testing"},{"key":"crv210008r58","unstructured":"American College of Surgeons. ACS COVID-19 registry. American College of Surgeons; 2021. Accessed August 3, 2021. https:\/\/www.facs.org\/quality-programs\/covid19-registry"},{"key":"crv210008r59","unstructured":"Alliance for Clinical Trials in Oncology website. Accessed August 3, 2021. https:\/\/www.allianceforclinicaltrialsinoncology.org\/main\/member\/standard.xhtml?path=%2FMember%2FCOVID-19"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2783489\/jamaoncology_desai_2021_rv_210008_1639155108.40905.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T16:25:37Z","timestamp":1639671937000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2783489"}},"subtitle":["A Review of the Registry-Based Pandemic Response"],"short-title":[],"issued":{"date-parts":[[2021,12,1]]},"references-count":61,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2021.4083","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12,1]]}}}